FR09C0062I2 - Anticorps de la il-1 beta humaine - Google Patents

Anticorps de la il-1 beta humaine

Info

Publication number: FR09C0062I2
Authority: FR; France
Prior art keywords: human; beta antibodies; antibodies; beta
Prior art date: 2000-08-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR09C0062C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-22

Filing date

2009-12-03

Publication date

2010-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9898090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0062(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-03 Application filed by Novartis AG filed Critical Novartis AG

2010-08-01 Publication of FR09C0062I1 publication Critical patent/FR09C0062I1/fr

2010-12-31 Application granted granted Critical

2010-12-31 Publication of FR09C0062I2 publication Critical patent/FR09C0062I2/fr

Status Active legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Cardiology (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)

FR09C0062C 2000-08-22 2009-12-03 Anticorps de la il-1 beta humaine Active FR09C0062I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0020685.4A GB0020685D0 (en)	2000-08-22	2000-08-22	Organic compounds
PCT/EP2001/009588 WO2002016436A2 (fr)	2000-08-22	2001-08-20	ANTICORPS DE LA IL-1β HUMAINE

Publications (2)

Publication Number	Publication Date
FR09C0062I1 FR09C0062I1 (fr)	2010-08-01
FR09C0062I2 true FR09C0062I2 (fr)	2010-12-31

Family

ID=9898090

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR09C0062C Active FR09C0062I2 (fr)	2000-08-22	2009-12-03	Anticorps de la il-1 beta humaine

Country Status (36)

Country	Link
US (3)	US7446175B2 (fr)
EP (1)	EP1313769B2 (fr)
JP (2)	JP4271936B2 (fr)
KR (2)	KR20080056316A (fr)
CN (1)	CN100547003C (fr)
AR (1)	AR035581A1 (fr)
AT (1)	ATE396206T1 (fr)
AU (2)	AU2001295490B2 (fr)
BE (1)	BE2009C057I2 (fr)
BR (1)	BR0113420A (fr)
CA (1)	CA2420231C (fr)
CY (2)	CY1108779T1 (fr)
CZ (1)	CZ304470B6 (fr)
DE (2)	DE60134148D1 (fr)
DK (1)	DK1313769T4 (fr)
EC (1)	ECSP034490A (fr)
ES (1)	ES2305110T5 (fr)
FR (1)	FR09C0062I2 (fr)
GB (1)	GB0020685D0 (fr)
HU (2)	HU228159B1 (fr)
IL (2)	IL154465A0 (fr)
LU (1)	LU91624I2 (fr)
MX (1)	MXPA03001590A (fr)
MY (1)	MY130248A (fr)
NL (1)	NL300427I2 (fr)
NO (3)	NO332609B1 (fr)
NZ (2)	NZ524199A (fr)
PE (1)	PE20020319A1 (fr)
PL (1)	PL212480B1 (fr)
PT (1)	PT1313769E (fr)
RU (1)	RU2286351C2 (fr)
SI (1)	SI1313769T2 (fr)
SK (1)	SK288089B6 (fr)
TW (1)	TWI321568B (fr)
WO (1)	WO2002016436A2 (fr)
ZA (1)	ZA200301275B (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2426710A1 (fr) *	2000-11-08	2002-10-10	Human Genome Sciences, Inc.	Anticorps a liaison immunospecifique avec les recepteurs "trail"
US7361341B2 (en)	2001-05-25	2008-04-22	Human Genome Sciences, Inc.	Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en)	2001-05-25	2008-03-25	Human Genome Sciences, Inc.	Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
CA2824167C (fr) *	2002-09-06	2018-09-25	Amgen Inc.	Anticorps monoclonal therapeutique anti-il-1r1 humain
US7101978B2 (en) *	2003-01-08	2006-09-05	Applied Molecular Evolution	TNF-α binding molecules
EP1590369B1 (fr) *	2003-01-24	2016-03-16	Applied Molecular Evolution, Inc.	Antagonistes de l'il-1 beta humaine
GB0303337D0 (en)	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
US20040224893A1 (en) *	2003-05-06	2004-11-11	Li-Hsien Wang	Methods of using IL-1 antagonists to treat neointimal hyperplasia
NZ549040A (en) *	2004-02-17	2009-07-31	Schering Corp	Use for interleukin-33 (IL33) and the IL-33 receptor complex
AU2005216298B2 (en)	2004-02-26	2010-09-02	Baylor Research Institute	Compositions and methods for the systemic treatment of arthritis
AU2012213934B9 (en) *	2005-01-26	2013-07-25	Amgen Fremont Inc.	Antibodies against interleukin-1 beta
EP1851245B1 (fr) *	2005-01-26	2012-10-10	Amgen Fremont Inc.	Anticorps dirigés contre l'interleukine-1 beta
GB0509512D0 (en) *	2005-05-10	2005-06-15	Novartis Ag	Organic compounds
DK1899378T3 (da)	2005-06-21	2010-02-01	Xoma Technology Ltd	IL-1 beta-bindende antistoffer og fragmenter deraf
US20100015146A1 (en) *	2005-10-14	2010-01-21	Novo Nordisk A/S	Treating diabetes using inhibitors of il-1
TR201802449T4 (tr) *	2005-10-26	2018-03-21	Novartis Ag	Ailesel akdeniz hummasının anti ıl-1beta antikorları ile tedavisi.
BRPI0709977A2 (pt) *	2006-04-14	2011-08-02	Novartis Ag	uso de anticorpos de il-1 para o tratamento de distúrbios oftálmicos
CA2673592C (fr)	2006-12-20	2014-03-25	Xoma Technology Ltd.	Procedes de traitement de maladies associees a il-.beta.
CL2008001071A1 (es) *	2007-04-17	2009-05-22	Smithkline Beecham Corp	Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
EP2468301A1 (fr)	2007-05-29	2012-06-27	Novartis AG	Nouvelles indications pour une thérapie anti-IL-1-bêta
EP1997832A1 (fr) *	2007-05-29	2008-12-03	Ganymed Pharmaceuticals AG	Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
US8637029B2 (en) *	2007-12-20	2014-01-28	Xoma Technology Ltd.	Methods for the treatment of gout
BRPI0910482A2 (pt)	2008-04-29	2019-09-24	Abbott Lab	imunoglobinas de domínio variável duplo e usos das mesmas
PE20100092A1 (es) *	2008-06-03	2010-03-12	Abbott Lab	Inmunoglobulina con dominio variable dual y usos de la misma
BRPI0913366A8 (pt)	2008-06-03	2017-07-11	Abbott Lab	Imunoglobulinas de domínio variável duplo e seus usos
ES2398693T3 (es) *	2008-06-06	2013-03-21	Xoma Technology Ltd.	Métodos para el tratamiento de la artritis reumatoide
NZ603698A (en)	2008-07-08	2014-03-28	Abbvie Inc	Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
EP2341936A4 (fr) *	2008-09-05	2012-07-25	Xoma Technology Ltd	PROCÉDÉS POUR LE TRAITEMENT OU LA PRÉVENTION DES MALADIES ASSOCIÉES À IL-1ß
MX2011004199A (es) *	2008-10-20	2011-05-24	Abbott Lab	Anticuerpos que unen a il-18 y metodos para purificar los mismos.
US8298533B2 (en) *	2008-11-07	2012-10-30	Medimmune Limited	Antibodies to IL-1R1
EP2196476A1 (fr) *	2008-12-10	2010-06-16	Novartis Ag	Formulation d'anticorps
EP2427209A1 (fr) *	2009-05-06	2012-03-14	Novartis AG	Thérapie par combinaison d'anticorps anti-il1-
US8389474B1 (en) *	2009-07-14	2013-03-05	Alan Anson Wanderer	Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
KR20120060877A (ko) *	2009-09-01	2012-06-12	아보트 러보러터리즈	이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en) *	2009-10-15	2013-05-23	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
WO2011051231A1 (fr)	2009-10-26	2011-05-05	F. Hoffmann-La Roche Ag	Procédé de fabrication d'une immunoglobuline glycosyle
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130065662A (ko)	2010-05-07	2013-06-19	조마 테크놀로지 리미티드	ⅠＬ-1β 관련 병태의 치료 방법
US8735546B2 (en)	2010-08-03	2014-05-27	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
PE20140229A1 (es)	2010-08-26	2014-03-27	Abbvie Inc	Inmunoglobulinas con dominio variable dual y usos de las mismas
JP2014519480A (ja)	2011-04-15	2014-08-14	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	癌で使用される抗ｉｌ−１ｒ１阻害物質
WO2013007763A1 (fr)	2011-07-12	2013-01-17	Universität Zürich	Modulateurs de la voie d'il-1β de l'inflammasome nlrp3 destiné à la prévention ou au traitement de l'acné
DE102011083595A1 (de)	2011-09-28	2013-03-28	Bayer Pharma AG	Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
BR112014007253A2 (pt) *	2011-09-30	2017-03-28	Novartis Ag	uso de anticorpos que se ligam a il-1beta
US20140348848A1 (en)	2011-12-02	2014-11-27	Dhananjay Kaul	Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
CN104144947B (zh)	2011-12-14	2017-10-27	艾伯维德国有限责任两合公司	用于诊断和治疗铁相关病症的组合物和方法
WO2013087912A1 (fr)	2011-12-16	2013-06-20	Synthon Biopharmaceuticals B.V.	Composés et méthodes de traitement de maladies inflammatoires
US20150017157A1 (en)	2011-12-19	2015-01-15	Xoma (Us) Llc	Methods for treating acne
AR089529A1 (es)	2011-12-30	2014-08-27	Abbvie Inc	Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
HRP20200964T1 (hr) *	2012-02-13	2020-10-30	Agency For Science, Technology And Research	IL-ß NEUTRALIZIRAJUĆA LJUDSKA MONOKLONSKA PROTUTIJELA
CN103588878A (zh) *	2012-08-15	2014-02-19	江苏泰康生物医药有限公司	一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用
KR20180008921A (ko)	2012-11-01	2018-01-24	애브비 인코포레이티드	항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
CA2888583C (fr)	2012-11-05	2022-03-29	Delenex Therapeutics Ag	Elements de liaison a il-1 beta
AU2013344796B2 (en)	2012-11-16	2016-11-10	Novartis Ag	Use of IL-1 beta binding antibodies for treating peripheral arterial disease
WO2014095808A1 (fr)	2012-12-17	2014-06-26	Delenex Therapeutics Ag	Anticorps contre il-1 bêta
EP2935589A1 (fr)	2012-12-18	2015-10-28	Novartis AG	Compositions et procédés qui utilisent une étiquette peptidique qui se lie au hyaluronane
CN105324396A (zh)	2013-03-15	2016-02-10	艾伯维公司	针对IL-1β和/或IL-17的双重特异性结合蛋白
WO2015083120A1 (fr)	2013-12-04	2015-06-11	Novartis Ag	Utilisation d'anticorps de liaison à il-1β
WO2015198243A2 (fr)	2014-06-25	2015-12-30	Novartis Ag	Compositions et procédés pour protéines à action longue
EP3160991A2 (fr)	2014-06-25	2017-05-03	Novartis AG	Compositions et procédés permettant d'obtenir des protéines à action prolongée
WO2016008851A1 (fr) *	2014-07-14	2016-01-21	Boehringer Ingelheim International Gmbh	Anticorps anti-il-1b
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh)	2014-10-14	2021-01-21	瑞士商諾華公司	針對ｐｄ－ｌ１之抗體分子及其用途
CA2963606A1 (fr)	2014-11-10	2016-05-19	F.Hoffmann-La Roche Ag	Anticorps anti-ang2 et methodes d'utilisation correspondantes
AU2015345323A1 (en)	2014-11-10	2017-04-06	F. Hoffmann-La Roche Ag	Bispecific antibodies and methods of use in ophthalmology
WO2016094881A2 (fr)	2014-12-11	2016-06-16	Abbvie Inc.	Protéines de liaison à lrp-8
WO2016193931A1 (fr)	2015-06-04	2016-12-08	Novartis Ag	Utilisation d'anticorps de liaison il-1 bêta pour traiter une maladie artérielle périphérique
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
DK3317301T3 (da)	2015-07-29	2021-06-28	Immutep Sas	Kombinationsterapier omfattende antistofmolekyler mod lag-3
US20180222982A1 (en)	2015-07-29	2018-08-09	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (fr)	2015-07-29	2021-09-15	Novartis AG	Polythérapies comprenant des molécules d'anticorps tim-3
WO2017106656A1 (fr)	2015-12-17	2017-06-22	Novartis Ag	Molécules d'anticorps anti-pd-1 et leurs utilisations
US11377656B2 (en)	2016-03-10	2022-07-05	Novartis Ag	Chemically modified messenger RNA's
EP3487584A1 (fr)	2016-07-21	2019-05-29	Novartis AG	Utilisation de l'anticorps canakinumab se liant à l'il-1 beta pour le traitement ou le soulagement des symptômes de la sarcoïdose pulmonaire.
US10610104B2 (en)	2016-12-07	2020-04-07	Progenity, Inc.	Gastrointestinal tract detection methods, devices and systems
WO2018112256A1 (fr)	2016-12-14	2018-06-21	Progenity Inc.	Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur d'il-1
UY37758A (es)	2017-06-12	2019-01-31	Novartis Ag	Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
JP2020524694A (ja)	2017-06-22	2020-08-20	ノバルティスアーゲー	がんの処置における使用のためのＩＬ−１β結合性抗体
WO2018235056A1 (fr)	2017-06-22	2018-12-27	Novartis Ag	Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer
EP3655961A4 (fr) *	2017-07-17	2021-09-01	Massachusetts Institute of Technology	Atlas de cellules de tissus barrières sains et malades
US20200199220A1 (en)	2017-08-25	2020-06-25	Tom THURENS	Use of canakinumab
RU2020113234A (ru) *	2017-09-13	2021-10-13	Новартис Аг	ПРИМЕНЕНИЕ АНТИТЕЛ, СВЯЗЫВАЮЩИХ IL-1β, ДЛЯ ЛЕЧЕНИЯ АЛКОГОЛЬНОГО ГЕПАТИТА
TW201922291A (zh)	2017-11-16	2019-06-16	瑞士商諾華公司	組合療法
TW201946652A (zh)	2018-05-09	2019-12-16	瑞士商諾華公司	康納單抗(canakinumab)之用途
UY38251A (es)	2018-06-01	2019-12-31	Novartis Ag	Moléculas de unión contra bcma y usos de las mismas
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
GB2575853A (en) *	2018-07-25	2020-01-29	Robert Wotherspoon Hugh	IL-1ß binding antibody
CN110818793A (zh) *	2018-08-14	2020-02-21	中山康方生物医药有限公司	抗IL-1β的抗体、其药物组合物及其用途
WO2020039401A1 (fr)	2018-08-24	2020-02-27	Novartis Ag	Traitement comprenant des anticorps se liant à il-1 βeta et ses combinaisons
CN113383016B (zh) *	2018-11-07	2022-09-13	三生国健药业（上海）股份有限公司	结合人IL-1β的抗体、其制备方法和用途
US20220249814A1 (en)	2018-11-19	2022-08-11	Progenity, Inc.	Methods and devices for treating a disease with biotherapeutics
KR20210106437A (ko)	2018-12-20	2021-08-30	노파르티스 아게	3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
EP3897613A1 (fr)	2018-12-21	2021-10-27	Novartis AG	Utilisation d'anticorps de liaison à il-1bêta
GB201901187D0 (en)	2019-01-29	2019-03-20	Autolus Ltd	Treatment of neurotoxicity and/or cytokine release syndrome
EP3924055B1 (fr)	2019-02-15	2024-04-03	Novartis AG	Dérivés de 3-(1-oxoisoindoline-2-yl)pipéridine-2,6-dione substitués et leurs utilisations
CN113490528B (zh)	2019-02-15	2024-12-03	诺华股份有限公司	3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US20220356240A1 (en) *	2019-09-26	2022-11-10	Beth Israel Deaconess Medical Center, Inc.	Anti-inflammatory therapy in arrhythmogenic cardiomyopathy (acm)
EP4073115A1 (fr)	2019-12-09	2022-10-19	Novartis AG	Anticorps anti-interleukine 1 bêta pour le traitement de la drépanocytose
CN121197633A (zh)	2019-12-13	2025-12-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置
MX2022007759A (es)	2019-12-20	2022-07-19	Novartis Ag	Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
TWI793503B (zh)	2020-01-20	2023-02-21	美商美國禮來大藥廠	抗IL-1β抗體
CN115551538A (zh)	2020-01-21	2022-12-30	拓维创新生物科技(香港)有限公司	干扰IL-1β受体信号转导的药剂
WO2021231798A1 (fr)	2020-05-13	2021-11-18	Disc Medicine, Inc.	Anticorps anti-hémojuvéline (hjv) pour le traitement de la myélofibrose
WO2021257539A1 (fr) *	2020-06-16	2021-12-23	Academia Sinica	ANTICORPS CIBLANT L'INTERLEUKIN-1β ET LEURS UTILISATIONS
CN115916199A (zh)	2020-06-23	2023-04-04	诺华股份有限公司	包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
WO2022023907A1 (fr)	2020-07-31	2022-02-03	Novartis Ag	Méthodes de sélection et de traitement de patients présentant un risque élevé d'événements cardiaques indésirables majeurs
US20240025993A1 (en)	2020-11-06	2024-01-25	Novartis Ag	Cd19 binding molecules and uses thereof
JP2023549257A (ja)	2020-11-18	2023-11-22	ノバルティスアーゲー	Ｎｌｒｃ４－ｇｏｆインフラマソーム病の処置における使用のための二特異性抗体
WO2022167916A1 (fr)	2021-02-03	2022-08-11	Novartis Ag	Utilisation d'anticorps se liant à l'il-1b pour le traitement de troubles neuro-inflammatoires
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
JP2024519893A (ja)	2021-05-24	2024-05-21	ノバルティスアーゲー	変形性関節症の治療方法
WO2022269451A1 (fr)	2021-06-22	2022-12-29	Novartis Ag	Anticorps bispécifiques destinés à être utilisés dans le traitement de l'hidrosadénite suppurée
WO2025068957A1 (fr)	2023-09-29	2025-04-03	Novartis Ag	Anticorps bispécifiques destinés à être utilisés dans l'abaissement du risque d'événements de maladie cardiovasculaire chez des sujets connus pour être un support d'expansion clonale de lignées cellulaires hématopoïétiques avec des mutations somatiques
GB202400340D0 (en)	2024-01-10	2024-02-21	Wotherspoon Hugh Robert	IL-1B binding antibody

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US534858A (en) *		1895-02-26		Workman s time-recorder
CA1172789A (fr)	1980-09-25	1984-08-14	Hideo Kasahara	POLYMERE RENFERMANT UN POLYAMIDE LIE A UN COPOLYMERE QUI CONTIENT UN IMIDE D'ACIDE CARBOXYLIQUE INSATURE EN .alpha.,.beta.
US4772685A (en)	1985-10-02	1988-09-20	Merck & Co., Inc.	Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4935343A (en) *	1986-08-08	1990-06-19	Syntex (U.S.A.) Inc.	Monoclonal antibodies for interleukin-1β
ATE87659T1 (de)	1986-09-02	1993-04-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
DK590387A (da) *	1986-11-13	1988-05-14	Otsuka Pharma Co Ltd	Antistoffer mod interleukin-1
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
EP0364778B1 (fr)	1988-10-01	1996-03-13	Otsuka Pharmaceutical Co., Ltd.	Anticorps contre l'interleukine-1 bêta
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
FR2640146B1 (fr)	1988-12-08	1993-12-24	Commissariat A Energie Atomique	Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2018248A1 (fr)	1989-06-07	1990-12-07	Clyde W. Shearman	Anticorps monoclonaux contre le recepteur alpha-beta de cellules t humaines, leur production et leur utilisation
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
EP1690934A3 (fr)	1990-01-12	2008-07-30	Abgenix, Inc.	Génération d'anticorps xenogéniques
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
US5545806A (en) *	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) *	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) *	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de)	1990-08-29	2005-08-15	Genpharm Int	Transgene mäuse fähig zur produktion heterologer antikörper
US5661016A (en) *	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) *	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
JP3714683B2 (ja) *	1992-07-30	2005-11-09	生化学工業株式会社	抗リウマチ剤
US5429614A (en)	1993-06-30	1995-07-04	Baxter International Inc.	Drug delivery system
WO1995001997A1 (fr) *	1993-07-09	1995-01-19	Smithkline Beecham Corporation	ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
US6309636B1 (en) *	1995-09-14	2001-10-30	Cancer Research Institute Of Contra Costa	Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US6051228A (en)	1998-02-19	2000-04-18	Bristol-Myers Squibb Co.	Antibodies against human CD40
GB0001448D0 (en)	2000-01-21	2000-03-08	Novartis Ag	Organic compounds

2000
- 2000-08-22 GB GBGB0020685.4A patent/GB0020685D0/en not_active Ceased
2001
- 2001-08-16 PE PE2001000817A patent/PE20020319A1/es not_active Application Discontinuation
- 2001-08-17 AR ARP010103946A patent/AR035581A1/es active IP Right Grant
- 2001-08-20 JP JP2002521531A patent/JP4271936B2/ja not_active Expired - Lifetime
- 2001-08-20 KR KR1020087012282A patent/KR20080056316A/ko not_active Ceased
- 2001-08-20 DE DE60134148T patent/DE60134148D1/de not_active Expired - Lifetime
- 2001-08-20 NZ NZ524199A patent/NZ524199A/en not_active IP Right Cessation
- 2001-08-20 EP EP01976118A patent/EP1313769B2/fr not_active Expired - Lifetime
- 2001-08-20 CA CA2420231A patent/CA2420231C/fr not_active Expired - Lifetime
- 2001-08-20 SK SK213-2003A patent/SK288089B6/sk not_active IP Right Cessation
- 2001-08-20 ES ES01976118T patent/ES2305110T5/es not_active Expired - Lifetime
- 2001-08-20 DE DE122009000078C patent/DE122009000078I1/de active Pending
- 2001-08-20 DK DK01976118.8T patent/DK1313769T4/da active
- 2001-08-20 US US10/362,082 patent/US7446175B2/en not_active Expired - Lifetime
- 2001-08-20 AU AU2001295490A patent/AU2001295490B2/en not_active Expired
- 2001-08-20 CN CNB018145140A patent/CN100547003C/zh not_active Expired - Lifetime
- 2001-08-20 WO PCT/EP2001/009588 patent/WO2002016436A2/fr not_active Ceased
- 2001-08-20 CZ CZ2003-505A patent/CZ304470B6/cs not_active IP Right Cessation
- 2001-08-20 HU HU0300806A patent/HU228159B1/hu active Protection Beyond IP Right Term
- 2001-08-20 IL IL15446501A patent/IL154465A0/xx unknown
- 2001-08-20 SI SI200130844T patent/SI1313769T2/sl unknown
- 2001-08-20 PL PL360358A patent/PL212480B1/pl unknown
- 2001-08-20 AU AU9549001A patent/AU9549001A/xx active Pending
- 2001-08-20 BR BR0113420-5A patent/BR0113420A/pt not_active IP Right Cessation
- 2001-08-20 AT AT01976118T patent/ATE396206T1/de active
- 2001-08-20 NZ NZ534269A patent/NZ534269A/en not_active IP Right Cessation
- 2001-08-20 KR KR1020037002161A patent/KR100910789B1/ko not_active Expired - Lifetime
- 2001-08-20 PT PT01976118T patent/PT1313769E/pt unknown
- 2001-08-20 MX MXPA03001590A patent/MXPA03001590A/es active IP Right Grant
- 2001-08-20 RU RU2003107564/13A patent/RU2286351C2/ru active Protection Beyond IP Right Term
- 2001-08-21 MY MYPI20013927A patent/MY130248A/en unknown
- 2001-08-22 TW TW090120626A patent/TWI321568B/zh not_active IP Right Cessation
2003
- 2003-02-13 IL IL154465A patent/IL154465A/en active Protection Beyond IP Right Term
- 2003-02-17 ZA ZA200301275A patent/ZA200301275B/en unknown
- 2003-02-19 EC EC2003004490A patent/ECSP034490A/es unknown
- 2003-02-21 NO NO20030827A patent/NO332609B1/no not_active IP Right Cessation
2008
- 2008-08-01 JP JP2008199799A patent/JP2008295456A/ja active Pending
- 2008-08-11 CY CY20081100840T patent/CY1108779T1/el unknown
- 2008-09-26 US US12/238,502 patent/US7993878B2/en not_active Expired - Fee Related
2009
- 2009-11-24 NL NL300427C patent/NL300427I2/nl unknown
- 2009-11-25 LU LU91624C patent/LU91624I2/fr unknown
- 2009-11-30 BE BE2009C057C patent/BE2009C057I2/fr unknown
- 2009-12-03 FR FR09C0062C patent/FR09C0062I2/fr active Active
- 2009-12-09 CY CY2009019C patent/CY2009019I2/el unknown
2011
- 2011-06-29 US US13/171,631 patent/US8273350B2/en not_active Expired - Fee Related
2012
- 2012-11-21 NO NO2012018C patent/NO2012018I1/no unknown
2013
- 2013-04-26 HU HUS1300015C patent/HUS1300015I1/hu unknown
2017
- 2017-10-11 NO NO2017052C patent/NO2017052I2/no unknown

Also Published As

Publication number	Publication date
CY2009019I1 (el)	2012-01-25
JP2004506448A (ja)	2004-03-04
CN1484652A (zh)	2004-03-24
IL154465A0 (en)	2003-09-17
US7993878B2 (en)	2011-08-09
US20090081732A1 (en)	2009-03-26
CA2420231C (fr)	2011-04-26
JP2008295456A (ja)	2008-12-11
BR0113420A (pt)	2003-07-29
DK1313769T3 (da)	2008-09-15
EP1313769B2 (fr)	2011-11-09
US20040063913A1 (en)	2004-04-01
CZ304470B6 (cs)	2014-05-21
HU228159B1 (en)	2013-01-28
NO2012018I2 (no)	2012-11-21
BRPI0113420B8 (fr)	2021-05-25
SI1313769T1 (sl)	2008-10-31
ATE396206T1 (de)	2008-06-15
HUP0300806A3 (en)	2005-09-28
IL154465A (en)	2010-11-30
MXPA03001590A (es)	2003-06-04
RU2286351C2 (ru)	2006-10-27
NO2017052I2 (no)	2018-05-14
HUS1300015I1 (hu)	2021-05-28
ECSP034490A (es)	2003-03-31
CZ2003505A3 (cs)	2003-05-14
AU2001295490B2 (en)	2005-06-16
GB0020685D0 (en)	2000-10-11
NL300427I1 (en)	2010-02-01
NO20030827D0 (no)	2003-02-21
AU9549001A (en)	2002-03-04
US8273350B2 (en)	2012-09-25
NO332609B1 (no)	2012-11-19
HK1061403A1 (en)	2004-09-17
KR20080056316A (ko)	2008-06-20
SK288089B6 (sk)	2013-06-03
ES2305110T3 (es)	2008-11-01
ES2305110T5 (es)	2012-03-13
US20110256151A1 (en)	2011-10-20
CY1108779T1 (el)	2012-01-25
WO2002016436A3 (fr)	2002-06-20
CN100547003C (zh)	2009-10-07
PE20020319A1 (es)	2002-06-11
KR20030034140A (ko)	2003-05-01
BE2009C057I2 (fr)	2021-01-28
CY2009019I2 (el)	2017-07-12
PL212480B1 (pl)	2012-10-31
JP4271936B2 (ja)	2009-06-03
FR09C0062I1 (fr)	2010-08-01
SI1313769T2 (sl)	2012-01-31
EP1313769B1 (fr)	2008-05-21
BRPI0113420B1 (pt)	2002-02-28
WO2002016436A2 (fr)	2002-02-28
HUP0300806A2 (hu)	2003-12-29
LU91624I9 (fr)	2018-11-19
TWI321568B (en)	2010-03-11
DE122009000078I1 (de)	2010-03-25
MY130248A (en)	2007-06-29
NL300427I2 (en)	2010-02-01
NO20030827L (no)	2003-04-14
SK2132003A3 (en)	2003-10-07
EP1313769A2 (fr)	2003-05-28
NO2012018I1 (no)	2012-12-10
KR100910789B1 (ko)	2009-08-04
PL360358A1 (en)	2004-09-06
DK1313769T4 (da)	2011-12-05
CA2420231A1 (fr)	2002-02-28
US7446175B2 (en)	2008-11-04
NO2017052I1 (no)	2017-10-11
AR035581A1 (es)	2004-06-16
LU91624I2 (fr)	2010-01-25
ZA200301275B (en)	2004-04-02
NZ524199A (en)	2004-09-24
DE60134148D1 (de)	2008-07-03
PT1313769E (pt)	2008-08-26
NZ534269A (en)	2006-04-28

Publication	Publication Date	Title
FR09C0062I2 (fr)	2010-12-31	Anticorps de la il-1 beta humaine
IS6779A (is)	2003-04-11	Mannlíkt mótefni gegn LT-beta-R
NO20023266D0 (no)	2002-07-05	Antistoffer mot humant IL-1
EP1396500A4 (fr)	2005-02-02	Anticorps anti-trail-r
DE60023971D1 (de)	2005-12-22	Wegwerfunterwäsche
DE60129523D1 (de)	2007-09-06	Wegwerfunterwäsche
DE60104769D1 (de)	2004-09-16	Wegwerfunterwäsche
DE60137900D1 (de)	2009-04-23	Wegwerfunterwäsche
EP1423431A4 (fr)	2005-04-27	Anticorps anti-vla-1
NO20026063L (no)	2003-02-27	Antistoffer mot human MCP-1
DE60144260D1 (de)	2011-04-28	Wegwerfwindel
DE60125524D1 (de)	2007-02-08	Wegwerfhöschen
DE60018495D1 (de)	2005-04-14	Tamponeinführhilfe
DE60018142D1 (de)	2005-03-24	Tamponapplikator
DE60109968D1 (de)	2005-05-19	Wegwerfwindel
DE60129917D1 (de)	2007-09-27	Wegwerfunterwäsche
DE60120890D1 (de)	2006-08-03	Wegwerfwindel
FI20000346L (fi)	2001-08-16	Järjestely biosignaalin mittaamiseksi
DE60029737D1 (de)	2006-09-14	Wegwerfwindel
DE60142667D1 (de)	2010-09-09	Wegwerfunterwäsche
DE60125492D1 (de)	2007-02-08	Wegwerfwindel
EP1178829A4 (fr)	2005-06-08	Anticorps monoclonal humain
ATE258035T1 (de)	2004-02-15	Wegwerfartikel für menschliche fäkalien
DE60028272D1 (de)	2006-07-06	Wegwerfunterwäsche
DE60105927D1 (de)	2004-11-04	Wegwerfwindel